Pipeline

This area shows current statistics on our products. Our brain and liver cancer treatment has received (*) Orphan Drug Designation from EMA.

SI053

Basic Research 100%
Pre-formulation 100%
Proof-of-concept 50%
Preclinical Safety 50%
GLP Toxicity 50%
Method Validation 70%
Protocol Design 80%

SA033

Basic Research 100%
Pre-formulation 70%
Proof-of-concept 80%
Preclinical Safety 40%
GLP Toxicity 100%
Method Validation 80%
Protocol Design 60%

BELOPENEM

Basic Research 70%
Pre-formulation 20%
Proof-of-concept 10%
Preclinical Safety 0%
GLP Toxicity 0%
Method Validation 0%
Protocol Design 0%
Contact Us